2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-115959
    Anticancer agent 34 2379335-06-3 98%
    Anticancer agent 34 (compound 9), a sulfonylurea derivative, is a potent antimicrobial and anticancer agent. Anticancer agent 34 inhibits the microbial growth of B. mycoides, E. coli, and C. albicans with a MIC between 0.156 and 0.039 mg/ml. Anticancer agent 34 inhibits A549, PC3 cell growth with IC50s of 8.4 µg/ml, 7.8 µg/ml, respectively.
    Anticancer agent 34
  • HY-115961
    Anticancer agent 36 2902563-76-0 98%
    Anticancer agent 36 (compound 11), a sulfonylurea derivative, is a potent antimicrobial and anticancer agent. Anticancer agent 36 inhibits the microbial growth of B. mycoides, E. coli, and C. albicans with a MIC between 0.156 and 0.039 mg/L. Anticancer agent 36 inhibits A549, PC3 cell growth with IC50s of 19.7 µg/mL, 11.9 µg/mL, respectively.
    Anticancer agent 36
  • HY-115966
    COX-1/2-IN-1 2358849-47-3 98%
    COX-1/2-IN-2 is a potent COX1/2 inhibitor. COX-1/2-IN-2 exhibits significant inhibitory effect against COX-1 and COX-2 inhibitor with IC50 values of 13.9 ± 3.21 µM and 6.4±0.74 µM, respectively.
    COX-1/2-IN-1
  • HY-115967
    COX-1/2-IN-2 2882832-86-0 98%
    COX-1/2-IN-2 is a potent COX1/2 inhibitor. COX-1/2-IN-2 exhibits significant inhibitory effect against COX-1 and COX-2 inhibitor with IC50 values of 9.7 ± 0.09 µM and 4.6 ± 1.45 µM, respectively.
    COX-1/2-IN-2
  • HY-115971
    Anti-Trypanosoma cruzi agent-1 2854299-38-8 98%
    Anti-Trypanosoma cruzi agent-1 (Compd E5) posseses anti-T. gondii activity.
    Anti-Trypanosoma cruzi agent-1
  • HY-115972
    Anti-Trypanosoma cruzi agent-2 2863602-85-9 98%
    Anti-Trypanosoma cruzi agent-1 (Compd 3b), selective compound against NINOA trypomastigote (IC50 = 0.51 µM) and INC-5 epimastigote form (IC50 = 3.06 µM), posseses anti-T. gondii activity.
    Anti-Trypanosoma cruzi agent-2
  • HY-115976
    COX-2-IN-10 98%
    COX-2-IN-10 is a potent COX-2 inhibitor. COX-2-IN-10 inhibits the production of PGE2 in concentration dependent manner (IC50=2.54 µM). COX-2-IN-10 inhibits the expression of iNOS and COX-2 on mRNA and protein level . COX-2-IN-10 inhibits the production of IL-6, TNF-α and IL-1β.
    COX-2-IN-10
  • HY-115977
    Aldose reductase-IN-3 1390616-76-8 98%
    Aldose reductase-IN-3 (Compound 5) is a potent and moderately selective inhibitor of aldose reductase (AR) with an IC50 of 3.99 μM. Aldose reductase has recently emerged as a molecular target that is involved in various inflammatory diseases, including sepsis. Aldose reductase-IN-3 has the potential for the research of sepsis.
    Aldose reductase-IN-3
  • HY-116015
    Dihomo-γ-Linolenic acid methyl ester 21061-10-9 98.00%
    Dihomo-γ-Linolenic acid methyl ester is the methyl ester form of Dihomo-γ-Linolenic Acid (DGLA) (HY-A0143). Dihomo-γ-Linolenic acid is an n-6 polyunsaturated fatty acid that is metabolized mainly through the cyclooxygenase (COX) pathway to the anti-inflammatory eicosanoid prostaglandin (PG) E1. Dihomo-γ-Linolenic acid has anti-inflammatory and antiproliferation effects.
    Dihomo-γ-Linolenic acid methyl ester
  • HY-116033
    BMS-363131 384829-65-6 98%
    BMS-363131 is a selective inhibitor for tryptase, with an IC50 <1.7 nM. BMS-363131 is hydrolytic stable at pH=7 and pH=9. BMS-363131 attenuates the astham in a guinea pig model.
    BMS-363131
  • HY-116050
    17(S)-HETE 183509-25-3 98%
    17S-HETE is arachidonic acid metabolite through cytochrome P-450 pathways. 17S-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy.
    17(S)-HETE
  • HY-116088
    W123 1345982-24-2 98%
    W123, a FTY720 analog, is a competitive sphingosine 1-phosphate type 1 (S1P1) receptor antagonist. W123 is measured by GTPγS activation, MAPK recruitment, cell migration, and ligand-induced receptor internalization.
    W123
  • HY-116099
    ER-819762 1155773-15-1 98%
    ER-819762 is an orally active, highly selective prostaglandin E2 (PGE2) EP4 receptor antagonist with an EC50 of 70 nM against human EP4 receptor. ER-819762 can be used for rheumatoid arthritis research.
    ER-819762
  • HY-116120
    N-Acetyldesloratadine 117796-52-8 99.93%
    N-Acetyldesloratadine (SCH-37370) is a potent, orally active dual antagonist of platelet-activating factor (PAF) and histamine. N-Acetyldesloratadine inhibits PAF-induced aggregation of human platelets, with an IC50 of 0.6 µM. N-Acetyldesloratadine can be used for the study of allergic diseases, such as asthma.
    N-Acetyldesloratadine
  • HY-116145
    MHY884 1393371-35-1 98%
    MHY884 is a tyrosinase inhibitor that suppresses UVB-induced activation of NF-κB signaling pathway through the downregulation of oxidative stress. MHY884 suppresses oxidative stress in the melanoma cells and attenuates UVB-induced oxidative stress, resulting in reduced NF-κB activity in irradiated mice. MHY884 is promising for research of UVB-induced skin damage.
    MHY884
  • HY-116184
    PF-05387252 1604034-71-0 98%
    PF-05387252 is a potent and selective IRAK4 inhibitor with the activity of inhibiting endogenous TLR signaling pathways. PF-05387252 has shown anti-inflammatory activity in experimental models and may have potential clinical application value in inhibiting psoriasis. Although PF-05387252 and its related compounds have shown anti-inflammatory effects in animal models, their efficacy in inhibiting psoriasis has not yet been verified.
    PF-05387252
  • HY-116208
    Dalcotidine 120958-90-9 98%
    Dalcotidine (KU-1257) is an orally active and competitive histamine H2 receptor antagonist. Dalcotidine promotes the healing of chronic ulcers and inhibits gastric acid secretion.
    Dalcotidine
  • HY-116209
    Pyrogallol triacetate 525-52-0 98%
    Pyrogallol triacetate (NSC 24068) is used as an antiasthmatic.
    Pyrogallol triacetate
  • HY-116230
    BI-L-45 XX 111317-77-2 98%
    BI-L-45 XX is an orally active anti-inflammatory agent. BI-L-45 XX can inhibit the release of neutrophil enzymes and chemotaxis, and is used in the study of adjuvant-induced arthritis.
    BI-L-45 XX
  • HY-116243
    Vitacoxib 1374128-90-1 98%
    Vitacoxib is an Imidazole (HY-D0837) derivative, selective COX-2 inhibitor, anti-inflammatory agent. Vitacoxib can be used in the research of inflammatory diseases, pain and fever.
    Vitacoxib
Cat. No. Product Name / Synonyms Application Reactivity